Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2021163365 - SARS-COV-2 VACCINE

Publication Number WO/2021/163365
Publication Date 19.08.2021
International Application No. PCT/US2021/017709
International Filing Date 11.02.2021
IPC
A61K 39/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 2319/735
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
70containing domain for protein-protein interaction
735containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
C12N 2770/20034
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants
  • THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]/[US]
  • BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US]/[US]
  • TRUSTEES OF DARTMOUTH COLLEGE [US]/[US]
Inventors
  • GRAHAM, Barney
  • CORBETT, Kizzmekia
  • ABIONA, Olubukola
  • HUTCHINSON, Geoffrey
  • MCLELLAN, Jason
  • WRAPP, Daniel
  • WANG, Nianshuang
Agents
  • SCOTT, Gregory K.
  • RYBAK, Sheree Lynn
Priority Data
62/972,88611.02.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SARS-COV-2 VACCINE
(FR) VACCIN CONTRE LE SARS-COV-2
Abstract
(EN) SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.
(FR) L'invention concerne des trimères d'ectodomaine S du SARS-CoV-2 stabilisés dans une conformation de préfusion, des molécules d'acide nucléique et des vecteurs codant pour ces protéines, ainsi que des méthodes d'utilisation et des procédés de production associés. Dans plusieurs modes de réalisation, les trimères d'ectodomaine S du SARS-CoV-2 et/ou les molécules d'acide nucléique peuvent être utilisés pour générer une réponse immunitaire contre la protéine S du SARS-CoV-2 chez un sujet, par exemple, une réponse immunitaire qui inhibe une infection par le SARS-CoV-2 chez le sujet.
Latest bibliographic data on file with the International Bureau